STREAM (Standardized Treatment Regimen of Anti-TB Drugs for Patients with MDR-TB) Stage 1 demonstrated non-inferior efficacy of a shortened regimen (the Short regimen) for rifampicin-resistant TB (RR-TB) compared to the contemporaneous WHO-recommended regimen. This regimen included moxifloxacin and clofazimine, known to cause QT prolongation, and severe prolongation was more common on the Short regimen. This study investigated risk factors for QT prolongation with the Short regimen.
Recent Abstracts
Information About New Federal Regulations for Opioid Treatment Programs (OTPs)
Centering Country Ownership and Leadership: The Data for Health Initiative’s Approach
Mass Media Campaigns
Data for Health: Advancing Gender Equity
The Index of Tobacco Control Sustainability
Index of Tobacco Control Sustainability (ITCS): India Subnational Tobacco Control
Index of Tobacco Control Sustainability (ITCS): Indonesia Subnational Tobacco Control
Considerations for Planning Childhood Blood Lead Surveillance
Air Quality Monitoring Toolkit: Assessing Second-Hand Smoke in Hospitality Venues
Association between high-threshold practices and buprenorphine treatment termination